Keywords: Byetta, Eli Lilly, Amylin, Diabets, Label changes, FDA, Kidney problems
US FDA revises Byetta label to reflect possible kidney problems
Article | 03 November 2009
The US Food and Drug Administration yesterday acted on new safety information about possible kidney function problems, including kidney failure, ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- Negative US patent ruling for Novo Nordisk on Prandin
- Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
- US Supreme Court says patent settlement can "sometimes" be illegal
- Daiichi Sankyo files for Japanese approval of Prasugrel
